生化自调控基因疗法用于局灶性癫痫
过去20年抗癫痫药物进展有限,约三分之一癫痫患者经单药或多药治疗仍发作。病毒载体介导的基因转移可基于癫痫发生机制设计靶向治疗。本文描述一种自调控抗癫痫基因疗法,依赖细胞外谷氨酸升高时抑制神经元,在啮齿类局灶性癫痫模型中有效且耐受良好。
要点
- 该基因疗法以细胞外谷氨酸升高为触发信号抑制神经元。
- 在啮齿类局灶性癫痫模型中有效且耐受良好。
- 设计旨在降低临床转化障碍。
核心结论
- 自调控抗癫痫基因疗法在啮齿类局灶性癫痫模型中有效且耐受良好,可能降低临床转化障碍。
研究设计与样本
- 研究为病毒载体介导的基因转移策略,在啮齿类局灶性癫痫模型中进行评估。
- 该疗法依赖细胞外谷氨酸升高时对神经元产生抑制。
主要发现
- 该自调控抗癫痫基因疗法在啮齿类局灶性癫痫模型中有效。
- 该疗法在啮齿类局灶性癫痫模型中耐受良好。
局限性
- 原文指出既往类似策略的临床转化受可能影响认知、记忆、感觉或运动相关环路的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the introduction of more than one dozen new antiepileptic drugs in the past 20 years, approximately one-third of people who develop epilepsy continue to have seizures on mono- or polytherapy1. Viral-vector-mediated gene transfer offers the opportunity to design a rational treatment that builds on mechanistic understanding of seizure generation and that can be targeted to specific neuronal populations in epileptogenic foci2. Several such strategies have shown encouraging results in different animal models, although clinical translation is limited by possible effects on circuits underlying cognitive, mnemonic, sensory or motor function. Here, we describe an autoregulatory antiepileptic gene therapy, which relies on neuronal inhibition in response to elevations in extracellular glutamate. It is effective in a rodent model of focal epilepsy and is well tolerated, thus lowering the barrier to clinical translation.
引用
- Lieb A, Qiu Y, Dixon CL, et al. Biochemical autoregulatory gene therapy for focal epilepsy. Nat Med. 2018. PMID: 29988123. doi:10.1038/s41591-018-0103-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。